Pharmalot... Pharmalittle... Good Morning
Good morning, folks, and apologies for the late start, but we encountered a tech problem this morning that delayed our usual opening. But that is all behind us now, which means we must get cracking. After all, this is shaping up to be an especially busy week and we trust that you relate. To cope, yes, we are downing cups of stimulation. Our flavor today is Cinnamon Hazelnut Creme, a special blend that we found in the wilds of Pennsylvania. Meanwhile, here are some tidbits. We wish you luck conquering the world today and, as always, remind you to stay in touch...
Genzyme To Invest $80M In Fabrazyme Plant (Genetic Engineerin...
Source: Pharmalot - October 15, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Big Pharma’s Expansion Into Emerging Markets - a tale of bribery and
corruption
The drug industry is faced with two big challenges: First, declining prescription drug sales, especially in the United States, and second, losing patent protection for many profitable drugs. To make up for these down drifts, the industry is relying increasingly on new markets such as China and Africa. That expansion, however, is tainted by unsavory commercial practices.The Economist Intelligence Unit projects $166 billion in drug sales in China by 2017, making it a natural market for companies looking for further growth.In Africa, the size of the market is still small. However, the rapid growth of many big cities offers in...
Source: PharmaGossip - October 15, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Up And Down The Ladder... Job Changes
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone?
And here is our regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Melinta Therapeutics hired Lyn Baranowski as senior vp, corporate develop...
Source: Pharmalot - October 11, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Pharmalot... Pharmalittle... The Weekend Nears
And so, another working week will soon draw to a close. This is, as you know, our treasured signal to daydream about weekend plans. Today, however, the daydreaming begins early because we are officially off today, although we have obviously stopped for a few moments to conduct some business here. In any event, our agenda is filled with excitement, such as celebrating a birthday with one of the Pharmalot ancestors and taking Mrs. Pharmalot to yet another installment in our 'Let's-See-Them-Before-They-Die' concert series. But what about you? Anything interesting planned? How about catching up with someone special or reading ...
Source: Pharmalot - October 11, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Purple Haze: How the Purple Pill is Fighting Maine on Cheap Canadian Imports
In case you haven't heard, the pharmaceutical industry -- i.e., PhRMA -- is suing Maine, attempting to block a new law that goes into effect today. "The law, the first of its kind, sanctions the direct purchase of mail-order drugs from some foreign pharmacies. It has ignited a court battle with the pharmaceutical industry and set the stage for a broader fight over access to less-costly medication" (see here for the story plus a copy of PhRMA's complaint and Maine's motion to dismiss). PhRMA contends that the practice could expose residents to tainted or counterfeit medication. "It's not a safety issue," Republican Gov. Pau...
Source: Pharma Marketing Blog - October 9, 2013 Category: Pharma Commentators Tags: PurpleZone AstraZeneca Drug Importation Purple Pill counterfeit medicine Source Type: blogs
Investigating the fallout of a suicide - BMJ
This study was a comparison of atypical antipsychotics for the treatment of first episodes of schizophrenia (the CAFE study). The study’s structure was that of a Phase 4 randomized, double blind trial comparing the effectiveness of three different atypical antipsychotic drugs: Zyprexa (olanzapine), Risperdal (risperidone) and Seroquel (quetiapine), with each patient to be treated for a year.After about two weeks on study treatment in the hospital, Markingson was discharged to a halfway house. His mother, Mary Weiss, raised repeated concerns about his condition, questioning his involvement in the trial, but he eventually ...
Source: PharmaGossip - October 9, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
AstraZeneca's Get Moving America campaign features guess who?
(Source: PharmaGossip)
Source: PharmaGossip - October 8, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
NIH and Other Public Private Partnerships to Research Treatments for Multiple Diseases
Over the past few weeks, the National Institutes of Health (NIH) has made a number of important announcements regarding collaborations with industry as well as the funding of several new research initiatives. Below is a summary of these stories.
NIH Partners With Eli Lilly and Others on Rare Diseases
FierceBiotechResearch reported that NIH selected four (4) new preclinical drug development studies to uncover new therapies for rare diseases. The projects will be funded through the Therapeutics for Rare and Neglected Diseases (TRND) program under NIH's National Center for Advancing Translational Sciences, NCATS, whic...
Source: Policy and Medicine - October 4, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
Pharmalot... Pharmalittle... Good Morning
Rise and shine, everyone. The middle of the week is here, which is, generally, a busy time. Our morning, in fact, got off to an usually interesting start thanks to National Public Radio and WNYC, a local affiliate, which called us to discuss the Merck reorganization (you can listen here). We do this sort of thing, now and again, in case you were not aware. We are also available for conferences, bar mitzvahs and satires. While you ponder the possibilities, here are some tidbits to start the day. Hope you have a smashing time at work and do stay in touch...
J&J Says Dispute With Boehringer May Cause Doxil Shortage (Bloom...
Source: Pharmalot - October 2, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
A Crestor Blog Ad About a Crestor TV Ad About a Crestor TV Ad. Humor Fails to Educate.
AstraZeneca just posted a Crestor ad about a Crestor ad about a Crestor ad on AZ Health Connections, which is "A blog for AstraZeneca's US business." The blog post -- see screen capture below -- was written by Rod Wooten, Commercial Brand Leader, CRESTOR. It's an authentic direct-to-consumer (DTC) ad and includes all the FDA-required information, including the brief statement about major side effects.The post is titled "AstraZeneca Takes a New Advertising Approach to Engage & Educate Consumers" (find it here). I have a few words to say about the "new" approach below, but right now let's just savor the "unique" approach...
Source: Pharma Marketing Blog - October 1, 2013 Category: Pharma Commentators Tags: corporate blogs AstraZeneca Cholesterol Crestor DTC Source Type: blogs
Pharmalot... Pharmalittle... Good Morning
Good morning, folks, and nice to see you again. We hope the weekend was relaxing and refreshing, because yet another working week has just begun. You knew this would happen, yes? So did we. And to prepare, we have once again brewed a cup of stimulation to help us along. As always, we invite you to join us. After all, there is no shame in getting some assistance to fire up your brain first thing in the morning. Meanwhile, here are some tidbits. Have a grand day and do stay in touch...
Bayer Hires Pfizer's Brandicourt To Run Healthcare Operations (Reuters)
Roche Cancer Drug Shrinks Tumors In 26 Percent Of Smokers (Bloomberg ...
Source: Pharmalot - September 30, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Pharmalot... Pharmalittle... The Weekend Nears
And so, another working week is about to draw to a close. Not a moment too soon, yes? As you may recall, this is our treasured signal to daydream about weekend plans and we have a modest agenda planned. High on our list is spending time with our short people, following by tidying up around the castle and napping here and there. As for you, anything special planned? We have mentioned before that this is a fine time to visit an apple orchard or simply enjoy the great outdoors. Of course, you could reach out to assorted important people in your life or simply do nothing and enjoy the moment. Whatever you do, have a grand time...
Source: Pharmalot - September 20, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Pharmalot... Pharmalittle... Good Morning
Hello, everyone, and how are you today? Here we are at the mid-week point, which means there is much to do. Nonetheless, we are heartened by the warm, shiny sun hovering over the Pharmalot corporate campus, where baby bunnies are frolicking in the weeds and another cup of stimulation is brewing. So, time to get cracking. Here are a few items of interest to help you along. As always, we wish you a wonderful day and look forward to staying in touch...
Former Genentech CEO And Google Announce New Biotech (The New York Times)
China Crackdown Over Bribery Charges Hurts Pharma Sales (Reuters)
Obamacare Prompts Concerns Over Spec...
Source: Pharmalot - September 18, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
GlaxoChinaGate contd. Analysis - Bribery scandal dents Big Pharma sales
in China, GSK hardest hit
By Adam Jourdan, Kazunori Takada and Ben HirschlerSHANGHAI/LONDON (Reuters) - A crackdown on corruption in China's pharmaceutical sector has hurt sales at international and local firms, with many doctors at Chinese hospitals refusing to see drug representatives for fear of being caught up in the widening scandal.Britain's GlaxoSmithKline Plc, the group at the centre of the furore, has suffered the most. Industry insiders expect its China drug sales growth to slow sharply or even reverse in the third quarter after a 14 percent year-on-year rise in the three months to end-June.But GSK - accused by Chinese police in July of u...
Source: PharmaGossip - September 18, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Not Lost in Translation: Barcelona, Catalonia, and Global Pharmaguy
I recently attended the 3rd Annual Pharma eMarketing Congress hosted by Fleming Europe in Barcelona, Spain. While there, I managed to mix business, fun, and politics in the same trip.This Congress has never failed to deliver and proves to me that in order to reap greater profits -- i.e., learn new things, meet new people -- you have to "outsource" yourself and travel to Europe, Asia, and South America. At least that's my strategy as a "Global Brand." The pharmaceutical industry, after all, is a global industry.On the day I arrived -- without my luggage! -- I was interviewed by Teresa Bau Puig (@tbau_uoc), a free-lance jour...
Source: Pharma Marketing Blog - September 17, 2013 Category: Pharma Commentators Tags: Conference Europe pharmaguy social media Source Type: blogs
